康寧傑瑞製藥-B(09966.HK)2024年溢利1.66億元 同比扭虧為盈
格隆匯3月25日丨康寧傑瑞製藥-B(09966.HK)公吿，截至2024年12月31日止年度錄得總收入人民幣6.4億元，同比增長192.58%；年度錄得溢利人民幣1.66億元，同比扭虧為盈；每股盈利0.17人民幣元。
公司是一家中國領先的生物製藥公司，在ADC、雙特異性抗體和多功能蛋白質工程方面擁有完善的專有技術平台。公司的使命是通過運用公司特有的藥物發現及開發能力，為全球患者提供世界一流的創新治療用生物製劑。公司認為該等能力可通過公司強大的研發往績記錄得到證明，並得到公司專有技術、平台及專業知識的支持。
於2024年11月，專注於醫藥行業的專業雜誌《E藥經理人》授予公司"2024中國醫藥創新企業100強"和"2024中國醫藥創新企業技術賽道TOP5"的稱號。於2024年11月，在"2024健康中國傳播大會"上，中國醫藥衞生文化協會、中國醫院協會以及國家衞生健康委員會百姓健康頻道(CHTV)授予公司"2024中國藥品企業品牌影響力TOP100"稱號。
集團將繼續通過公司獨有的藥物發現及開發能力，努力為全球患者提供世界一流的創新治療用生物製劑。憑藉公司強大的自主研發能力和技術平台，發現、驗證及選擇領先的候選藥物，以豐富早期管線，並將重心放在ADC上。公司亦將繼續優化製造工藝及技術，以提升產品質量並降低成本。為最大化公司全球專利資產的商業價值，公司亦將繼續積極尋求更多戰略性合作機會，例如共同開發、聯合開發合作及對外授權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
